ROIV is trading at $33.83, up 5.0% versus the comparison close of $32.21 during regular trading. This is a price-movement alert; no separate company-specific catalyst was searched for this follow-up.
π’ ROIV extends move to 5.0% up
Roivant Sciences Ltd
Related News
ROIV
Roivant Announces FDA Approval for LISRAYAβ’, a New Dermatomyositis Treatment
ROIV
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
ROIV
Roivant's Brepocitinib Clears Skin in Phase 3, Targeting 2026 FDA Approval
ROIV
Roivant's 7% Pop on a Narrower Loss and a Drug Launch Six Weeks Away β Is the Market Pricing in a Future That Hasn't Arrived?
ROIV